ProStrakan drug gets Swedish approval

Mar 7 2008

Cancer pain treatment given the go ahead

ProStrakan has gained marketing authorisation in Sweden for cancer pain drug Rapinyl.

The product will be branded as Abstral in Sweden and is expected to be launched in the third quarter of this year.

Dr Wilson Totten, chief executive of Galashiels based ProStrakan, was pleased with the cofirmation.

He said: "The Swedish Regulatory Authority’s decision to issue a Marketing Authorisation for Rapinyl (Abstral) while the EU regulatory procedure is still under way underlines their continued support for Europe-wide approval of this product."